Proof of Concept Study of Cognitive Improvement in Patients With Alzheimer's Disease
NCT ID: NCT00501111
Last Updated: 2014-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
659 participants
INTERVENTIONAL
2007-07-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease
NCT01137526
Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
NCT01466088
ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776
Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
NCT04730635
Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
NCT06304883
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Placebo
No interventions assigned to this group
2
donepezil
Donepezil
3
AZD3480
AZD3480
3 oral doses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD3480
3 oral doses
Donepezil
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical prognosis of probable Alzheimer's disease
* Patient must have a caregiver visiting the patient at least three times weekly
Exclusion Criteria
* Major depressive disorder, other major psychiatric disorder
* Use of acetylcholinesterase inhibitor or memantine for treatment of Alzheimer's disease within 8 weeks prior to enrollment
* Impaired vision and/or hearing making cognitive testing difficult
60 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca AZD3480, Medical Science Director
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Graz, Osterreich, Austria
Research Site
Innsbruck, Osterreich, Austria
Research Site
Vienna, Osterreich, Austria
Research Site
Linz, , Austria
Research Site
Aalst, Belgium, Belgium
Research Site
Antwerp, Belgium, Belgium
Research Site
Hasselt, Belgium, Belgium
Research Site
Leuven, Belgium, Belgium
Research Site
Sint-Truiden, Belgium, Belgium
Research Site
Pleven, , Bulgaria
Research Site
Plovdiv, , Bulgaria
Research Site
Rousse, , Bulgaria
Research Site
Sofia, , Bulgaria
Research Site
Varna, , Bulgaria
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Peterborough, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Greenfield Park, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Verdun, Quebec, Canada
Research Site
Regina, Saskatchewan, Canada
Research Site
Brno, , Czechia
Research Site
Havlíčkův Brod, , Czechia
Research Site
Hradec Králové, , Czechia
Research Site
Kladno, , Czechia
Research Site
Litoměřice, , Czechia
Research Site
Nový Jičín, , Czechia
Research Site
Olomouc, , Czechia
Research Site
Ostrava - Poruba, , Czechia
Research Site
Prague, , Czechia
Research Site
Prostějov, , Czechia
Research Site
Bad Saarow, , Germany
Research Site
Berlin, , Germany
Research Site
Dresden, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Heidelberg, , Germany
Research Site
Kiel-kronshagen, , Germany
Research Site
Leipzig, , Germany
Research Site
Lübeck, , Germany
Research Site
Magdeburg, , Germany
Research Site
Mannheim, , Germany
Research Site
München, , Germany
Research Site
Nuremberg, , Germany
Research Site
Piteşti, Argeş, Romania
Research Site
Târgu Mureş, Mureș County, Romania
Research Site
Bucharest, , Romania
Research Site
Iași, , Romania
Research Site
Sibiu, , Romania
Research Site
Moscow, , Russia
Research Site
Saint Petersburg, , Russia
Research Site
Smolensk, , Russia
Research Site
Palma de Mallorca, Balearic Islands, Spain
Research Site
Salamanca, Castille and León, Spain
Research Site
Barcelona, Catalonia, Spain
Research Site
Hospitalet de Llobregat(barcel, Catalonia, Spain
Research Site
Salt (girona), Catalonia, Spain
Research Site
Terrassa, Catalonia, Spain
Research Site
Madrid, Madrid, Spain
Research Site
Castellon, Valencia, Spain
Research Site
Baracaldo (vizcaya), , Spain
Research Site
Uckfield, E Sussex, United Kingdom
Research Site
Southampton, Hampshire, United Kingdom
Research Site
Blackpool, Lancashire, United Kingdom
Research Site
Bradford, , United Kingdom
Research Site
London, , United Kingdom
Research Site
Peterborough, , United Kingdom
Research Site
Swindon, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
D3690C00010 Clinical Stusy Report Synopsis
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EuDract 2007-00835-24
Identifier Type: -
Identifier Source: secondary_id
D3690C00010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.